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ability of F. tularensis to propagate intracellularly is enhanced by the 
failure of lysosomes to fuse with the phagosome (Anthony et al., 
1991) and the lack of stimulation of a respiratory burst (Wilson 
et al., 1980; Fortier et al., 1994). F. tularensis appears to bind host 
cells by interacting with complement receptors (Clemens et al., 
2005). After entry into macrophages, the spacious phagosomes are 
rapidly modified to a tight phagosome (Clemens et al., 2005). In 
the initial phase of intracellular infection, F. tularensis resides in 
the membrane-bound phagosomes of macrophages and does not 
appear to replicate (Golovliov et al., 2003; Clemens et al., 2004; 
Santic et al., 2005a). Replication occurs once the bacterium escapes 
into the cytosol when the phagosomal membranes are damaged 
(Golovliov et al., 2003; Clemens et al., 2004; Santic et al., 2005a). 
The mechanisms for bacterial escape into the cytosol remain to 
be defined. It is also unclear how F. tularensis disseminates from 
infected host cells to uninfected cells in vivo. It is thought that F. 
tularensis-infected macrophages are lysed by bacterium-induced 
apoptosis (Lai et al., 2001; Lai and Sjostedt, 2003).
The virulence determinants of F. tularensis are not well under-
stood (Barker and Klose, 2007). The lipopolysaccharide (LPS) of 
F. tularensis has been extensively studied because of its unusu-
ally low toxicity in vitro and in vivo and potential as a vaccine 
component (Sandstrom et al., 1992; Ancuta et al., 1996). Several 
bacterial proteins have recently been implicated in F. tularensis 
pathogenesis. These include AcpA (Mohapatra et al., 2007), MglA/
MglB (Baron and Nano, 1998), and the proteins encoded by the 
IntroductIon
Francisella tularensis is a Gram-negative intracellular bacterium 
and causative agent of tularemia in humans and many other species 
(Sjostedt, 2007). There are four F. tularensis subspecies or biotypes: 
tularensis (type A), holarctica (type B), mediasiatica, and novicida. 
All F. tularensis subspecies are able to cause lethal infection in mice, 
but only the strains of types A and B are mostly associated with 
human disease (Keim et al., 2007). F. tularensis live vaccine strain 
(LVS) is a type B derivative. LVS is relatively avirulent in humans 
but causes a lethal infection in mice that highly resembles human 
tularemia (Eigelsbach and Downs, 1961; Anthony and Kongshavn, 
1987). The infection can be transmitted by inhalation of F. tularen-
sis-containing aerosols, bites of blood-sucking insects, handling of 
infected animal carcasses, and consumption of contaminated food 
or water. Respiratory tularemia has attracted the most attention 
because inhalation of as few as 10–50 live organisms of F. tularensis 
type A can cause disease and the mortality rate can be >30% by the 
respiratory route in the absence of antibiotic therapy (McCrumb, 
1961). As a result, F. tularensis type A strains are listed as a category 
A potential agent of bioterrorism (Dennis et al., 2001).
Francisella tularensis is able to infect a range of cell types, but 
its primary target during infection appears to be the macrophage 
(Clemens and Horwitz, 2007). The pathogenic mechanisms of F. 
tularensis infection are poorly understood. The extraordinary infec-
tivity of F. tularensis is correlated with its efficient uptake, survival, 
and replication within host cells (Clemens and Horwitz, 2007). The 
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iglABCD intracellular growth operon (Nano et al., 2004). Recent 
 whole-genome screens in F. tularensis strains Schu S4 (Qin and 
Mann, 2006; Kadzhaev et al., 2009), LVS (Maier et al., 2007; Su 
et al., 2007; Schulert et al., 2009), and U112 (Tempel et al., 2006; 
Weiss et al., 2007; Kraemer et al., 2009; Ahlund et al., 2010) have 
identified a large number of bacterial genes that are involved in F. 
tularensis growth in cultured macrophages and host tissues. Our 
recent study revealed that the capBCA genes of F. tularensis strain 
LVS are necessary for bacterial growth in the lungs of mice (Su 
et al., 2007). Growth as used here refers to the bacterial load in host 
tissues, which reflects the net outcome of bacterial replication and 
survival in the context of host defense.
In this study, we sought to understand how the capBCA locus 
contributes to F. tularensis pathogenesis. The in vivo growth kinet-
ics of LVS and the isogenic capBCA mutants were determined in 
the lungs, spleens, and livers of infected BALB/c mice at various 
stages of infection. Unmarked deletion of capBCA was generated 
to assess the significance of this gene locus in the virulence of type 
A virulent strain Schu S4. We further characterized the expression 
of capB and its impact on F. tularensis pathogenesis. Finally, the 
contribution of capBCA to intracellular growth of F. tularensis was 
evaluated in cultured macrophage lines. Our results suggest that 
the capBCA genes contribute to the virulence and pathogenesis of 
F. tularensis at least in part through enhancing bacterial intracel-
lular adaptation.
MaterIals and Methods
BacterIal straIns and cheMIcal reagents
Francisella tularensis LVS and its derivatives were cultured as 
described previously (Su et al., 2007). When necessary, kanamycin 
(10 μg/ml) or hygromycin (200 μg/ml) was added in the broth and 
agar media for selection purposes. F. tularensis Schu S4, originally 
isolated from a human case of tularemia (Eigelsbach et al., 1951), 
was obtained from the U.S. Army Medical Research Institute for 
Infectious Diseases (Frederick, MD, USA; Malik et al., 2007). The 
culture media and conditions for Schu S4 strain are the same as 
for LVS. Escherichia coli strains were grown in Luria-Bertani (LB) 
broth or on LB agar plates in the presence or absence of ampicillin 
(100 μg/ml), kanamycin (50 μg/ml), and hygromycin (200 μg/ml). 
All ingredients for bacterial culture media and other chemicals 
used in this work were obtained from Sigma (St. Louis, MO, USA) 
unless otherwise stated.
sIte-dIrected MutagenesIs In F. tularensis
Unmarked in-frame deletional mutations were generated in the 
capBCA locus of strains LVS and Schu S4 by allelic replacement 
and counterselection as described (Su et al., 2007). All genetic 
manipulations of strain Schu S4 were performed with the approval 
of the Centers for Disease Control and Prevention (CDC) in a 
CDC-certified ABSL-3/BSL-3 facility at Albany Medical College. 
The entire coding region of the capBCA genes was deleted in Schu 
S4 using the conjugative plasmid pST937. pST937 was previously 
used to generate an unmarked deletion in capBCA of LVS (Su 
et al., 2007). capB was deleted in LVS in a similar manner with a 
few modifications. An 814-bp fragment downstream of capB was 
PCR amplified from LVS genomic DNA using primers Pr1073 
(5′-TACGAGAATTCTATAGTTTTAAGATTAAACAGGAGAAA-3′) 
and Pr1074 (5′-CTTGTCTCGAGCATATTTGGATTAACCGAAG
ACC-3′). This fragment was digested with EcoRI and XhoI and 
cloned behind the 5′ fragment of capB in plasmid pST933 (Su et al., 
2007). The entire construct was subcloned into the EcoRV site of a 
suicide plasmid pMP590 (LoVullo et al., 2006), resulting in the plas-
mid pMP590::∆capB or pST968. We chose pMP590 to delete capB 
because of its better amenability in DNA cloning (partially due to its 
smaller size relative to pomp) and transformation (electroporation 
instead of conjugation for pDMK). pST968 was transferred into LVS 
by electroporation and selected for kanamycin resistance (10 μg/
ml) as described (LoVullo et al., 2006). To remove the inserted 
plasmid and generate desirable capB deletion, the kanamycin resist-
ant transformants were streaked on chocolate agar plates contain-
ing 5% (w/v) sucrose. The sucrose-resistant colonies were further 
screened for the loss of kanamycin resistance. The resulting clones 
were examined for the capB deletion by PCR amplification using the 
flanking primers Pr896 (5′-AGCTGCACCTGAGTTATTTGAT-3′) 
and Pr901 (5′-AAATGCAAATGCGTCGTTA-3′). The capB deletion 
was finally confirmed by DNA sequencing in strain ST1092, one of 
the resultant ∆capB mutants. ST1092 retains the sequence encoding 
the nine N-terminal amino acids of CapB. The lack of the CapB 
protein in the ∆capB strains was assessed by Western blot using 
a mouse anti-CapB antiserum as described in western blot. The 
resultant strain ST1092 was selected for further characterization.
coMpleMentatIon of capB deletIon
The capB deletion in strain ST1092 was in trans complemented 
with an E. coli–Francisella shuttle plasmid pST1032 containing the 
intact capB gene as described previously (Su et al., 2007). capB in 
pST1032 was driven by the Francisella groEL. pST1032 was elec-
troporated into strain ST1092 and selected with 200 μg/ml hygro-
mycin, resulting in strain ST1104. Production of the CapB protein 
in the complemented strains was assessed by western blot using a 
mouse antiserum against glutathione S transferase (GST)-CapB as 
described in Section “Antibodies and Western blotting.”
gst-capB fusIon proteIn expressIon
A recombinant CapB was expressed as a fusion protein with the 
GST essentially as described (Lu et al., 2006). capB was ampli-
fied from the genomic DNA of strain LVS with primers Pr885 
(5′-ATCCTGAATTCGGATCCATATTTTCTCCTGTTT-3′) and 
Pr1175 (5′-ACTAGACCCGGGAACTACTTTGGATTTTTGGTTA
ATTG-3′). This fragment was cloned into the XmaI/EcoRI site of the 
pGEX-2T expression vector (GE Healthcare Bio-Science, Piscataway, 
NJ, USA) in E. coli strain BL-21 (DE3). The resultant E. coli strain 
was processed to produce and purify a GST fusion protein (desig-
nated GST-CapB) by affinity chromatography with the Glutathione 
Sepharose 4 Fast Flow resins (GE Healthcare Bio-Sciences) accord-
ing to the supplier’s instructions. Protein concentration was deter-
mined by the Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA, 
USA) and analyzed by SDS-PAGE as described (Lu et al., 2006).
antIBodIes and Western BlottIng
Antiserum against the F. tularensis CapB was raised with the GST-
CapB fusion protein as described (Zhang et al., 1997). Female 
BALB/c mice (6–8 weeks old) were immunized with purified 
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fetal bovine serum at 37°C, 5% CO
2
; MH-S cells were cultured 
in RPMI 1640 medium containing 10% (v/v) fetal bovine serum 
and 0.05 mM 2-mercaptoethanol at 37°C. Intracellular lev-
els of F.  tularensis were assessed out as described (Santic et al., 
2005b). Briefly, 2.5 × 105 macrophages were cultured in 24-well 
plates (Hyclone, Logan, UT, USA) to approximately 80% con-
fluency. The F. tularensis LVS derivatives were grown in MHB 
broth to OD
600
 ∼ 1.2 (∼3 × 109 CFUs/ml), pelleted by centrifuga-
tion, and resuspended in pre-warmed RPMI1640 to OD
600
 ∼ 0.2 
(∼5 × 108 CFUs/ml). After brief rinse with PBS, macrophages were 
infected with the bacterial suspensions at a multiplicity of infec-
tion (MOI) of 100 (bacterium vs. macrophage) at 0 h. After 2 h of 
incubation at 37°C, the unbound bacteria were removed from the 
wells by washing with PBS. Extracellular bacteria were killed by 
incubation with the cell culture medium containing gentamicin 
(50 μg/ml) for 1 h at 37°C. The cells were extensively rinsed to 
remove residual gentamicin and then cultured without antibiotic. 
To monitor bacterial uptake and replication, the culture medium 
of infected macrophages was moved to sterile tubes to lyse the 
cells at 3, 24, and 48 h post-infection with pre-chilled water. The 
medium and lysates from each well were combined, diluted with 
sterile PBS, and spread onto chocolate agar plates for CFU counts. 
Each infection experiment was repeated at least three times.
fluorescence and electron MIcroscopy
For fluorescence microscopy, U937 macrophages were infected 
with F. tularensis LVS as described previously (Santic et al., 2005a). 
Briefly, differentiated U937 cells on 12-mm-diameter circular glass 
coverslips (Fisher Scientific, Pittsburgh, PA, USA) in 24-well culture 
plates were infected with LVS and its isogenic mutants at MOI of 10 
for 1 h. To synchronize the infection, infected cells were centrifuged 
at 150 × g for 5 min before incubation at 37°C in 5% CO
2
. After 1 h 
of incubation, infected cells were washed three times with 1× PBS 
followed by 1 h of gentamicin (50 μg/ml) treatment. Cells were then 
fixed in 4% paraformaldehyde for 30 min. Paraformaldehyde was 
removed by washing the wells three times with PBS. The infected 
cells were permeabilized with 1% Triton-X100 for the LAMP-1 
experiment. For the Cathepsin D experiments, the cells were per-
meabilized with acetone for 5 min at −20°C. Samples were stained 
with F. tularensis polyclonal antibody (1:4,000 dilution) and mouse 
monoclonal anti-LAMP-1 (H4B3; 1:500 dilution; Hybridoma Gene 
Bank) or anti-Cathepsin D (BD transduction; 1:500 dilution). Alexa 
fluor 594-conjugated anti-mouse secondary antibody (1:500 dilu-
tion) was used to stain the LAMP-1 and Cathepsin D. Alexa fluor 
488-conjugated secondary antibody (1:500 dilution) was used to 
stain F. tularensis. Co-localization of bacteria with LAMP-1 and 
Cathepsin D was analyzed with FV1000 Olympus confocal micro-
scope as described previously (Santic et al., 2005a,b, 2008). The 
bacteria associated with phagosomes and phagolysosomes were 
quantified by enumerating F. tularensis co-localized with LAMP-1/
Cathepsin D out of the total bacteria in 100 infected cells from 
more than 10 different fields for each strain. Each experiment was 
repeated at least once.
For electron microscopy, U937 macrophages growing in 6-well 
tissue culture plates were inoculated with F. tularensis as described 
above. Twenty-four hours post-inoculation, the wells were washed 
with 0.1 M Na Cacodylate buffer, pH 7.3 and incubated for 1 h with 
 GST-CapB every 2 weeks via the subcutaneous route for a total 
of three immunizations. The immunogen for each immunization 
consisted of 25 μg GST-CapB in 100 μl sterile phosphate-buffer 
saline (PBS) and 100 μl alum (Rehydrogel Low Viscosity Gel; Reheis, 
Berkeley Heights, NJ, USA) as described (Sun et al., 2004). Western 
blotting of F. tularensis proteins was performed with an enhanced 
chemiluminescence (ECL) Western Blot Kit (Pierce, Rockford, 
IL, USA) according to the supplier’s instructions. The GST-CapB 
antiserum and peroxidase-conjugated goat anti-mouse IgG anti-
body (Bio-Rad laboratories, Hercules, CA, USA) were used at a 
dilution of 1:1000 and 1:5000, respectively.
Mouse InfectIons
Infection experiments with F. tularensis LVS and its derivates were 
carried out in BALB/c mice as described (Su et al., 2007). All animal 
infection experiments were in compliance with the guidelines of the 
Institutional Animal Care and Use Committee at Albany Medical 
College. To prepare the F. tularensis inocula, frozen stocks of LVS 
and the isogenic capBCA mutants were individually diluted in PBS 
based on predetermined colony forming unit (CFU) values. Each 
preparation was serially diluted in PBS and plated to assess the 
actual CFUs of each inoculum immediately prior to the mouse 
infection experiments. Each inoculum was intranasally inoculated 
into groups of mice (female, 6–8 weeks old). Infected mice were 
sacrificed at various time points post-infection. The lungs, liver, 
and spleen were aseptically removed and processed to determine 
the CFU levels of LVS and the mutants in each organ as described 
(Su et al., 2007). To determine the virulence levels of the ∆capBCA 
mutants in the LVS and Schu S4 backgrounds, groups of five mice 
were intranasally infected with serial dilutions of the wild type and 
isogenic ∆capBCA strains. Infected mice were monitored daily for 
signs of morbidity and mortality for 21 days. Infection experiments 
with Schu S4 and all of its derivatives were carried out as described 
for strain LVS with the exception that all of the experiments associ-
ated with Schu S4 were performed and contained in a CDC-certified 
ABSL-3/BSL-3 facility at Albany Medical College.
To test the immuno-protection of ∆capBCA mutants, groups 
of five BALB/c mice were inoculated intranasally with different 
dosages of ST938. Mice injected with sterile PBS were used as con-
trol. Three weeks after immunization, each mouse was challenged 
intranasally with 40,000 CFU of LVS. Infected mice were monitored 
daily for clinical signs and mortality for 21 days.
hIstopathology
BALB/c mice were intranasally infected with F. tularensis LVS or 
isogenic mutants as described above. Mice, along with uninfected 
controls, were sacrificed to excise the lungs, liver, and spleen at day 7. 
The organs were fixed in 10% neutral-buffered formalin, processed 
using standard histological methods to obtain 5-μm-thick paraffin 
sections, and stained with H&E as described (Baron et al., 2007).
Macrophage InfectIon
The human monocytic cell line U937 (ATCC CRL-1593.2) and 
mouse alveolar macrophages MH-S cell line (ATCC CRL-2019) 
were obtained from the American Type Culture Collection 
(Manassas, VA, USA). U937 cells were maintained in Iscove’s 
modified Dulbecco’s medium (IMDM) supplemented with 10% 
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throughout the entire test period (Figure 1A). In sharp contrast to 
a 15.1-fold growth of LVS in the lungs of infected mice in initial 
24 h, the number of ∆capBCA dropped by 75% during the same 
infection period, indicating that the capBCA locus is required for 
bacterial growth in the initial phase of LVS infection. At days 2 
and 4, both LVS and ∆capBCA exhibited substantial growth, but 
the numbers of ∆capBCA were significantly lower when compared 
with that of LVS. At day 7, the bacterial levels of both LVS and 
∆capBCA were reduced bacterial burdens, likely due to the onset 
of the adaptive immunity. By 9 days post-inoculation, all of the 
LVS-infected mice died, whereas ∆capBCA-infected mice did not 
display any detectable sign of disease and remained disease-free 
throughout the 21-day infection period. Finally, ∆capBCA became 
undetectable from the lungs of the infected mice at days 14 and 21.
We also assessed the dissemination of ∆capBCA from lung to 
spleen and liver in the same BALB/c mice as described in Figure 1A. 
As early as 24 h post-inoculation, LVS were readily detected in the 
spleens (2,430 CFUs in average) and livers (42,840 CFUs in average), 
whereas ∆capBCA was barely detectable in these distal organs until 
day 4 (Figures 1B,C). Similar to the kinetics of bacterial burden in 
the lungs, the numbers of ∆capBCA were significantly lower than 
those of LVS in the spleens and livers from days 1 to 7. ∆capBCA 
became undetectable in the livers of all infected mice on days 14 
and 21. Interestingly, there were low levels of ∆capBCA detectable 
in the spleens of two and one mice (out of six) at days 14 and 21, 
respectively (see below for additional interpretations). We thus con-
clude that the capBCA genes are necessary for in vivo growth of F. 
tularensis LVS (bacterial replication and resistance to host killing).
ld50 and IMMuno-protectIon of lVs ∆capBca
The persistent presence of ∆capBCA in the spleens (Figure 1B) 
raised the possibility that the mutant is capable of better priming 
the adaptive immunity against F. tularensis LVS. To test this notion, 
we first attempted to assess the attenuation level of ∆capBCA by 
determining the LD
50
. Groups of BALB/c mice were intranasally 
infected with a wide range of bacterial doses (4.5 × 102–7 CFUs). 
None of the infected mice showed any appreciable symptoms or 
died from the infection during the 6-week period of observation 
(data not shown), indicating the LD
50
 of the ∆capBCA mutant 
a solution containing 2.5% glutaraldehyde/4% formaldehyde in 
0.1 M Na Cacodylate, pH 7.3. Following washing with Cacodylate 
buffer, the cells were post-fixed with 1.0% osmium tetroxide in 
0.1 M Na Cacodylate buffer, pH 7.3 for 1 h. The monolayers were 
washed with normal saline, and scraped with a Costar cell scraper 
into normal saline and gently pelleted by centrifugation. The pel-
lets were dehydrated in a graded Ethanol series and embedded 
in LR White medium (Polysciences, Inc.). Ultrathin sections were 
collected onto Formvar-coated grids, stained with uranyl acetate 
and lead citrate. Specimens were viewed and photographed with a 
JEOL 100CX transmission electron microscope using Kodak elec-
tron microscope film.
statIstIcal analysIs
A log-rank test was used to determine the level of significance for 
the Kaplan–Meier survival analyses. All other results were expressed 
as mean ± SEM and comparisons between the groups were made 
using Student’s t test. Differences between control and experimental 
groups were considered significant at p < 0.05 levels.
results
in vivo groWth kInetIcs of the lVs capBca Mutants
In our previous study (Su et al., 2007), the LVS mutant lacking the 
capBCA genes (∆capBCA) exhibited significantly impaired growth 
in the lungs of infected mice at day 7 post-intranasal inoculation. 
However, it was unclear whether the capBCA genes are required 
at the earlier and/or later stages of F. tularensis infection. We thus 
determined the in vivo growth kinetics of ∆capBCA by assessing 
the levels of bacterial burdens in the lungs, kidneys, and livers of 
infected BALB/c mice on days 1, 2, 4, 7, 14, and 21 post-intranasal 
inoculation.
To accurately determine the inoculation efficiency, we first deter-
mined bacterial loads in the lungs of infected mice immediately 
after intranasal inoculation. Mice infected with LVS or ∆capBCA 
(strain ST938) showed a similar level of bacteria (∼3 × 103 CFUs) 
in the lungs 1 h post-intranasal inoculation of 5 × 03 CFUs (day 0; 
Figure 1A). This indicated that ∆capBCA was effectively inoculated 
into the lungs of mice at a similar efficiency as the parent strain 
LVS. ∆capBCA displayed a significant growth deficiency in the lungs 
Figure 1 | In vivo growth of LVS ∆capBCA. (A) Bacterial burden in the 
lungs of BALB/c mice (n = 5) infected with LVS or isogenic ∆capBCA strain 
ST938 alone. Lung tissues were collected to determine the viable  
bacteria by plating various dilutions of tissue homogenates at days  
0, 1, 2, 4, 7, 14, and 21 post-inoculation. Bars indicate the mean log10CFU 
values ± SEM. Asterisks indicate p < 0.05 as determined by Student’s 
t test. (B) Bacterial burdens in the spleens of mice infected individually 
with LVS derivatives were determined as in (A). (C) Bacterial burdens in 
the livers of mice infected individually with LVS derivatives were determined  
as in (A).
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2007), the infection doses of the ∆capBCA mutant were accord-
ingly adjusted. While all of mice infected with 16 CFUs of Schu 
S4 died by day 9, the mortality rate of mice infected with ST965 
was significantly reduced in a dose-dependent manner (Figure 2). 
In general, the attenuation of the Schu S4 ∆capBCA mutant was 
less pronounced than that of the LVS counterpart in this model. 
Michell et al. (2010) recently reported that deletion of capB in Schu 
S4 led to >100-fold attenuation in virulence in a subcutaneous 
infection model of BALB/c mice. These findings thus indicated 
that the capBCA locus is necessary for the full virulence of human 
virulent F. tularensis type A strains.
characterIzatIon of F. tularensis capB
To gain more insight into the function(s) of the F. tularensis cap-
BCA locus, we further characterized capB. The coding sequence 
of capB in LVS was removed by allelic exchange. Three resulting 
strains (ST1092-4) were verified for the lack of capB as deter-
mined by PCR amplification (Figure 3A) and DNA sequencing 
(data not shown). Primers Pr896/Pr901 were expected to pro-
duce amplicons of 2,177 bp in LVS and 991 bp in ∆capB mutants 
ST1092-4. To determine the expression of the CapB protein, we 
also constructed a GST-CapB fusion protein in E. coli to generate 
an antiserum against CapB in mice. The F. tularensis CapB protein 
is predicted to contain 405 amino acids with the molecular mass 
of 44.9 kDa. As represented in Figure 3B, the antiserum reacted 
with a protein band of 44 kDa in LVS, which was completely 
absent in the isogenic ∆capB mutant ST1092. The missing band 
in ST1092 was restored in trans by the shuttle plasmid pST1032 
(strain ST1104). We thus concluded that the antiserum specifi-
cally detected the CapB protein. The CapB protein appears to be 
produced at a relatively low level under in vitro culture conditions 
because it was only detected when a large amount of the total 
bacterial lysates (∼2 × 109 CFU) was loaded in the protein gel. 
This was not due to a potential low titer of the antiserum because 
the antiserum readily detected CapB with ∼2 × 108 CFUs of the 
complementation strain ST1104 (data not shown). Apparent over-
production of CapB in ST1104 was likely due to the strength 
of the Francisella groEL promoter and/or copy number of the 
was >4.5 × 107 CFU. LVS has an LD
50
 of ∼4 × 103 CFUs in this 
infection model (Duckett et al., 2005); all of mice infected with 
∼8 × 103 CFUs of LVS died in the first 2 weeks of infection (data 
not shown). Therefore, LVS ∆apBCA is avirulent in this BALB/c 
mouse model.
We next tested immuno-protection of ∆capBCA against infec-
tion of F. tularensis LVS. Groups of five BALB/c mice were intra-
nasally infected (or immunized) with ST938 in a dose range of 
4.5 × 102–7 CFUs. The mice were intranasally challenged with 
40,000 CFUs of LVS (10 times of LVS LD
50
 in this model) 3 weeks 
post-immunization. All of the five unimmunized mice (negative 
control) died within 9 days following LVS challenge (Table 1). 
Similarly, the majority (80%) of the mice immunized with 450 
CFUs of ST938 succumbed to LVS challenge. In contrast, all of the 
mice immunized with higher doses of ST938 (4.5 × 103–7 CFUs) 
did not show appreciable sign of illness after the challenge with 
40,000 CFUs of LVS in the 4-week observation period (Table 1), 
indicating that ∆capBCA is able to induce strong adaptive immu-
nity against infection of F. tularensis LVS even at relative low 
doses of immunization (e.g., 103–4 CFUs). This result agrees with 
a recent report that an LVS ∆capB strain induces potent immuno- 
protection against LVS challenge (Jia et al., 2010). We further tested 
the immuno-protection potential of ∆capBCA against the chal-
lenges with type A virulent strain Schu S4 in a similar manner. 
None of the intranasal immunization doses (4.5 × 103–7 CFUs of 
strain ST938) conferred significant protection against intranasal 
challenge with 100 CFUs of Schu S4 (data not shown). The sharp 
difference in immuno-protection of LVS ∆capBCA against LVS 
and Schu S4 demonstrate the distinct requirements for protective 
immunity against infections of types A and B F. tularensis.
IMportance of capBca In type a F. tularensis
The gene sequence and organization of the capBCA locus are virtu-
ally identical between F. tularensis subsp. holarctica (type B) and 
subsp. tularensis (type A). We thus tested whether the capBCA 
genes are necessary for the virulence of F. tularensis type A viru-
lent strain Schu S4. The coding sequence of the capBCA locus in 
Schu S4 was deleted by allelic replacement and counter selection 
as described in Section “Materials and Methods.” As observed 
with the ∆capBCA mutants in LVS (Su et al., 2007), the Schu S4 
∆capBCA mutants did not show obvious growth defects under 
in vitro conditions (data not shown). ST965, one of the Schu S4 
∆capBCA mutants, was subjected to further characterization of 
its virulence in the lung infection mouse model. Since laboratory 
mice are extremely susceptible to Schu S4 infection (Malik et al., 
Table 1 | Protection of LVS ∆capBCA against lethal LVS infection.
immunization dose (CFu) Survived/total mice
0 0/5
4.5 × 102 1/5
4.5 × 103 5/5
4.5 × 104 5/5
4.5 × 105 5/5
4.5 × 106 5/5
4.5 × 107 5/5
Figure 2 | Contribution of capBCA to the virulence of type A F. 
tularensis. BALB/c mice (n = 5) were intranasally infected with the indicated 
doses of Schu S4 or isogenic ∆capBCA mutant ST965. Survival was 
monitored for 21 days. The results are expressed as Kaplan–Meier curves and 
p values determined using log-rank test. The data shown are a representative 
of two independent experiments.
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et al., 2007; Malik et al., 2007), the lungs of the  LVS-infected 
mice had severe inflammation and tissue damage at day 7 post-
infection as compared to the uninfected control (Figure 3D). In 
contrast, mice infected with ST1092 showed a relatively normal 
lung structure with little sign of inflammation. The lungs of mice 
infected with the capB complementation strain ST1104 exhibited 
a low level of tissue infiltration but the overall structure was rela-
tively normal. Together with the experimental data with ∆capBCA 
(Figure 1; Su et al., 2007), these results allowed us to conclude 
that capB itself is necessary for the fitness of F. tularensis LVS. 
Our data are also consistent with a very recent study reporting 
that an LVS ∆capB mutant is severely attenuated in BALB/c mice 
(Jia et al., 2010).
defIcIency of the capBca Mutants In Intra-Macrophage 
groWth
We sought to understand how the capBCA locus contributes to in 
vivo adaptation of F. tularensis. Since F. tularensis is a facultative 
intracellular pathogen, we tested whether the capBCA genes are 
required for intracellular growth of F. tularensis. We initially tested 
the intracellular infection of ∆capB and ∆capBCA in mouse MH-S 
macrophages, because this is a commonly used alveolar macrophage 
model derived from BALB/c mice (Mbawuike and Herscowitz, 
1989; Ibrahim-Granet et al., 2003). At the end of the gentamicin 
treatment (hour 0), ∆capB and ∆capBCA showed similar levels 
of the intracellular growth as the parent strain LVS (Figure 4A). 
Because F. tularensis does not appear to replicate in the first 3 h post-
infection (Golovliov et al., 2003; Clemens et al., 2004; Santic et al., 
2005a), the result indicated that capBCA locus is dispensable for 
the initial phase of intracellular infection (bacterial adherence and 
uptake). By 24 and 48 h post-inoculation, the macrophages infected 
with ∆capB or ∆capBCA showed significantly lower CFUs (approxi-
mately 14- to 22-fold reduction) as compared to the cells infected 
with LVS (Figure 4A). Noticeably, ∆capB and ∆capBCA behaved 
similarly in this assay, suggesting that capB carries out an impor-
tant function(s) in this locus. The growth defect of ∆capB was not 
due to the abnormal growth of the mutant in the culture medium 
because LVS and its capBCA derivatives showed obvious growth in 
the absence of macrophages under the same conditions (data not 
shown). The defect of ∆capB in intracellular growth was partially 
restored by in trans complementation (Figure 4A, ∆capB::capB). 
The complementation strain still exhibited significant deficiency 
(two- to threefold) in intracellular growth as compared to LVS, 
likely due to overexpression of capB on the complementation con-
struct (see Figure 3B). We were unsuccessful in our attempts to 
complement the entire capBCA locus due to technical difficulty in 
cloning the three genes in E. coli–Francisella shuttle vectors (data 
not shown).
We subsequently confirmed the impairment of ∆capB and 
∆capBCA in intracellular growth using human U937 macrophages. 
Like in MH-S cells, the intracellular growth defect of ∆capB and 
∆capBCA was only observed after the initial phase of infection 
(Figure 4B, hour 0). A noticeable difference between the MH-S 
and U937 results is the marginal effect of in trans complementa-
tion construct on the intracellular growth phenotype of ∆capB in 
U937 cells (Figure 4B, ∆capB::capB). A very recent study by Jia 
et al. (2010) also showed that an LVS ∆capB mutant is significantly 
complementation construct as reported by Charity et al. (2007). 
A second band detected by the antiserum in ST1104 may represent 
a smaller isoform of the F. tularensis CapB as reported for the B. 
anthracis CapB (Makino et al., 1989).
We further performed infection experiments with the ∆capB 
mutant ST1092 and isogenic complementation strain ST1104. 
The ∆capB mutant was significantly deficient in in vivo growth at 
day 7 post-intranasal inoculation compared to the parent strain 
LVS (Figure 3C; Figure A1 in Appendix). The attenuation phe-
notype of ST1092 was partially in trans restored in complementa-
tion strain ST1104. The same capB complementation construct 
also showed partial complementation in the transposon mutant 
JS2512 in our previous study (Su et al., 2007). This could be due to 
instability of the shuttle plasmid during infection in the absence of 
antibiotic selection and/or inappropriate in trans expression level 
of the CapB protein. We also examined the impact of capB on F. 
tularensis pathogenesis by comparing histopathology of the lungs 
from BALB/c mice intranasally infected with either LVS or iso-
genic ∆capB mutants. In agreement with previous studies (Baron 
Figure 3 | CapB expression and its impact on in vivo growth of 
F. tularensis. (A) Detection of the capB deletion by PCR. The sequence 
surrounding the capB gene was amplified from the genomic DNA of LVS or 
three isogenic ∆capB clones (ST1092-4). The PCR products were separated in 
a 1% agarose gel and stained with ethidium bromide. The sizes of the DNA 
standards are indicated in kilobase. (B) Western blot detection of the F. 
tularensis CapB. Cell lysates of LVS derivatives representing ∼2 × 109 CFUs 
were separated by SDS-PAGE, probed with the GST-CapB antiserum, and 
detected by an ECL method. (C) In vivo growth of the F. tularensis ∆capB 
mutant. BALB/c mice were infected individually with LVS (4,500 CFUs), 
ST1092 (5,100 CFUs), or ST1104 (4,800 CFUs) by intranasal inoculation. 
Bacterial levels in the lungs were assessed at day 7 as in Figure 1. (D) Lung 
histopathology of F. tularensis-infected mice. BALB/c mice were infected as in 
(C). Lung tissues were processed for H&E staining at day 7 post-infection. 
Magnification = 20×.
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As exemplified in Figures 5A,C, only a small fraction (31%) of 
wild type LVS were associated with LAMP-1 and the majority of 
LVS bacteria were found in cytosol by 2 h post-infection, suggesting 
successful escape of LVS from the phagosome to cytosol. In sharp 
contrast, the majority of ∆capB (61%) and ∆capBCA (72%) were 
found to be associated with LAMP-1 during the same infection. 
These LAMP-1 co-localization levels are close to that of inactivated 
LVS (73%). Similar to the intracellular growth data (Figure 4B), 
in trans complementation of ∆capB with the wild type gene on a 
shuttle plasmid had marginal effect on the LAMP-1 co-localization 
of the mutant (Figure 5C). This finding thus suggested that ∆capB 
and ∆capBCA were severely impaired in their ability to escape from 
the phagosomes into cytosol.
Consistent with the co-localization of both the mutants with 
LAMP-1, ∆capB (68%) and ∆capBCA (73%) predominantly co-
localized with Cathepsin D, a lysosomal marker, by 2 h post-infec-
tion (Figures 5B,C). As a positive control, only 27% of live LVS 
was co-localized with Cathepsin D, which is consistent with its 
ability to escape from the phagosome–lysosome fusion pathway. In 
contrast, the inactivated LVS was mostly associated with Cathepsin 
D (83%) in the same infection period. Similar to the result for 
LAMP-1 (Figure 5A), the capB complementation construct failed 
to restore the co-localization of ∆capB to the level exhibited by the 
wild type bacteria (Figures 5B,C). We subsequently confirmed these 
findings in a ∆capB mutant of F. novicida strain U112 (data not 
shown). These results strongly suggested that ∆capB and ∆capBCA 
are significantly impaired in their ability to arrest maturation of 
the phagosome.
Finally, we visualized ∆capB and ∆capBCA, and their sub-cellular 
localization in U937 macrophages by transmission electron micro-
scopy. We focused our analysis on the 24-h time point because 
the morphology of the infected macrophages was no longer intact 
beyond this infection period. As represented in Figure 6 (indicated 
by arrow heads), the LVS-infected cells contained numerous bac-
teria that appear to be free in the cytoplasm and surrounded by an 
electron lucent zone. However, in addition to the free bacteria, there 
were large numbers of partially degraded bacteria in vacuolar-like 
structures in the macrophages infected with ∆capB (strain ST1092) 
and ∆capBCA (strain ST938) as indicated by asterisks in Figure 6. 
This type of sub-cellular structures were rarely found in the LVS-
infected macrophages (data not shown). The structures containing 
apparently degraded bacteria were also readily detectable in the 
in trans complemented ∆capB (strain ST1104), indicating that the 
complementation construct failed to restore the impairment in 
∆capB. These bacterium-containing vacuolar-like structures are 
likely phagolysosomes or autophagosomes because most of them 
were surrounded by an identifiable membrane. Taken together, 
we conclude that the capBCA genes are required for F. tularensis 
phagosomal escape and/or arrest of phagosomal maturation.
dIscussIon
The F. tularensis capBCA genes are among the 95 virulence-asso-
ciated genes identified in our recent STM study (Su et al., 2007). 
Transposon insertions in each of the capBCA genes resulted in 
significantly impaired growth of F. tularensis LVS in the lungs of 
BALB/c mice 7 days post-intranasal inoculation. In this study, 
we sought to understand how this gene locus contributes to 
attenuated in intracellular growth in THP-1 macrophages. Together, 
these results demonstrate that the capBCA locus is required for 
intracellular growth of F. tularensis LVS.
suB-cellular localIzatIon of the capBca Mutants In 
Macrophages
Previous studies indicate that F. tularensis transiently resides in a 
LAMP-1 and LAMP-2 positive phagosomes before escape into the 
cytosol for replication (Santic et al., 2010). The existing data have 
shown a correlation between escape into the cytosol and loss of 
LAMP-1/2 co-localization (Checroun et al., 2006; Bonquist et al., 
2008; Asare and Abu Kwaik, 2010). Therefore, loss of co-localiza-
tion with LAMP-1 and LAMP-2 has been used as an indicator for 
cytosolic localization of F. tularensis (Buchan et al., 2009). Based 
on the importance of the capBCA genes in F. tularensis intracel-
lular growth (Figure 4), we reasoned that this locus might play 
a role in the phagosomal escape of the bacterium and/or arrest 
of phagosomal maturation. To test this possibility, we analyzed 
co-localization of ∆capB and ∆capBCA with LAMP-1 (a phago-
somal marker) and Cathepsin D (a lysosomal marker) in U937 
macrophages by immunofluorescence microscopy.
Figure 4 | intracellular growth of F. tularensis capBCA mutants. 
(A) Intracellular growth of LVS derivatives in MH-S macrophages. Macrophages 
were infected at a multiplicity of infection of ∼100:1 (bacterium vs. macrophage) 
with LVS, isogenic ∆capBCA (strain ST938), ∆capB (strain ST1092), or 
complemented ∆capB (∆capB::capB, strain ST1104). Total bacteria per well were 
enumerated at the indicated time points. Statistic significance between LVS and 
its isogenic capBCA mutants (p > 0.05) was determined using Student’s t test. 
(B) Intracellular growth of LVS derivatives in U937 macrophages. The infection 
experiments were carried out and analyzed as in (A).
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Figure 5 | Co-localization of F. tularensis capBCA mutants with 
phagosomal and phagolysosomal markers. (A) Representative images 
showing co-localization of the LVS capBCA mutants with the phagosomal 
marker LAMP-1.  F. tularensis and LAMP-1 were stained and visualized as 
described in Section “Materials and Methods.” (B) Representative images 
showing co-localization of the LVS capBCA mutants with phagolysosomal 
marker Cathepsin D. (C) Association of LVS capBCA mutants with LAMP-1 and 
Cathepsin D. The results are expressed as the percentage of bacteria 
co-localized with LAMP-1 or Cathepsin D out of total bacteria in 100 U937 cells. 
Statistic significance between LVS and its isogenic capBCA mutants (p > 0.05) 
was determined  using Student’s t test. The data shown are a representative of 
two independent experiments.
F. tularensis fitness and pathogenesis. Mouse infection experi-
ments demonstrated that the unknown function(s) provided 
by the capBCA genes is required for the fitness and virulence 
of F. tularensis LVS and human virulent type A strain Schu S4. 
This finding is consistent with the recent reports that deletion 
mutants in capB of LVS (Jia et al., 2010) and Schu S4 (Michell 
et al., 2010) are attenuated in BALB/c mice. The experiments 
with the LVS capBCA mutants indicated that the capBCA genes 
are necessary for F. tularensis growth (replication and survival) 
in target organs at various stages of infection. The results from 
macrophage infection experiments suggest that the capBCA 
genes enhance F. tularensis fitness and thus virulence by pro-
moting intracellular growth of the bacterium. This conclusion 
is supported by significant deficiency of ∆capB and ∆capBCA 
in intracellular growth in both MH-S and U937 macrophage 
models.
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It is unclear how the capBCA genes contribute to F. tularensis 
growth in macrophages and host tissues. F. tularensis CapB and 
CapC are homologous to the CapB and CapC proteins of Bacillus 
anthracis, the causative agent of anthrax (Koehler, 2002). CapB 
and CapC, together with CapA, CapD, and CapE in B. anthracis, 
are responsible for the biosynthesis of the capsule consisting of 
poly-γ-d-glutamic acids (PGA; Candela and Fouet, 2006). CapB, 
cytoplasmic protein, is the catalytic component of the Bacillus 
PGA synthesis complex (Troy, 1973). The PGA-based capsule in 
B. anthracis is a major virulence factor due to its antiphagocytic 
property (Koehler, 2002). Interestingly, recent genome studies have 
revealed homologs of the PGA biosynthetic genes in a group of 
highly diverse Gram-negative bacteria including F. tularensis and 
Fusobacterium nucleatum (Kapatral et al., 2002; Glockner et al., 
2003; Ren et al., 2003; Hou et al., 2004; Larsson et al., 2005). Candela 
et al. (2009) recently reported the production of PGA by the cap-
BCA genes of F. nucleatum. The capBCA loci of F. tularensis and F. 
nucleatum are highly similar in gene sequence and order. It is thus 
possible that the F. tularensis capBCA locus enhances the bacterial 
growth in macrophages and host tissues through PGA production. 
However, no PGA or capsule has been detected from F. tularensis 
in our preliminary trials (unpublished data) or previous studies 
(Raynaud et al., 2007; Michell et al., 2010).
The capBCA locus is highly conserved in genus Francisella. The 
sequences of the capBCA coding and intergenic regions are virtually 
identical among F. tularensis subsp. tularensis (type A) (Larsson 
et al., 2005; Beckstrom-Sternberg et al., 2007), holarctica (type B) 
(Chain et al., 2006; Petrosino et al., 2006; Barabote et al., 2009), 
and novicida (Brittnacher et al., 2007). A recent study also revealed 
the presence of a similar capBCA locus in Francisella philomiragia 
(Copeland et al., 2008). Like F. tularensis subsp. novicida, F. philomi-
ragia is a water-associated bacterium and less pathogenic to humans 
than F. tularensis subsp. tularensis and holarctica (Penn, 2005). Our 
infection experiments indicate that the capBCA locus is necessary 
for the in vivo fitness and full virulence of F. tularensis types A and 
B organisms. Weiss et al. (2007) also showed that the transposon 
mutants in the capB and capC genes of F. tularensis subsp. novicida 
are attenuated in a systemic infection mouse model. Considering 
that mammals may not be the natural reservoirs of F. tularensis 
(Oyston and Quarry, 2005), the uncharacterized function(s) of the 
capBCA locus in F. tularensis and perhaps other Francisella species 
may be evolutionarily selected for a survival advantage under non-
mammalian conditions.
It is noticeable that the attenuation level of the Schu S4 ∆capBCA 
mutant was significantly lower than that of the LVS counterpart 
in our intranasal infection model in BALB/c mice. This differ-
ence may be due to other Schu S4-specific factor(s) that might 
have overshadowed the impact of the capBCA locus in the mouse 
model. Laboratory mice are exceptionally susceptible to Schu S4 
infection (Rick Lyons and Wu, 2007). Alternatively, the capBCA 
locus operates in a different manner at the transcriptional and/or 
post-transcriptional level. Lindgren et al. (2007) recently reported 
that a deletion in the catalase-encoding katG of F. tularensis LVS 
led to significant attenuation in virulence, but a similar Schu S4 
∆katG mutant showed no attenuation in virulence. Finally, differ-
ent mouse strains and routes of infection have yielded variable 
outcomes with the F. tularensis capB mutants in terms of virulence 
The deficiency of the capBCA mutants in intracellular growth 
lies beyond the uptake (attachment/entry) phase of intracellular 
infection. Specifically, the capBCA locus appears to enhance the 
intracellular growth of F. tularensis by promoting bacterial escape 
from phagosomes. This notion is consistent with multiple obser-
vations in this study. ∆capB and ∆capBCA remained predomi-
nantly co-localized with the LAMP-1 (a phagosomal marker) and 
Cathepsin D (a phagolysosomal marker) in U937 macrophages 
by 2 h post-infection. Second, degraded bacteria were abundantly 
observed in vacuolar-like structures of the macrophages infected 
with ∆capB and ∆capBCA. In this regard, the capBCA mutants 
behaved similarly to the mutants of other F. tularensis genes that 
are involved in phagosomal escape, most notably, the iglABCD 
genes located within the Francisella pathogenicity island (FPI; Lai 
et al., 2004; Nano et al., 2004; Santic et al., 2005b, 2008; de Bruin 
et al., 2007). However, we noticed that the capBCA mutants were 
much less impaired than the mutants of iglC or mglA (encod-
ing a FPI regulator) in terms of intra-macrophage growth (data 
not shown). While the iglC or mglA mutants virtually lacked 
intra-macrophage growth, the capBCA mutants were still able 
to grow to a relatively high level under the same conditions 
(data not shown). This observation indicates that the capBCA 
and FPI genes perform distinct functions in terms of promot-
ing intracellular adaptation of F. tularensis. In short, it remains 
to be determined whether the capBCA mutants are defective in 
one or more of the following intracellular infection stages: (i) 
survival/escape from the phagosomes to the cytosol, (ii) arrest 
of phagosomal maturation, (iii) replication in the cytosol, and/
or (iv) re-infection of other cells.
Figure 6 | Sub-cellular ultra-structures of u937 macrophages infected 
by LVS capBCA mutants. Electron micrographs of human macrophages 
inoculated with F. tularensis LVS (A), ∆capBCA (ST938) (B), ∆capB (ST1092) 
(C), or complemented ∆capB (ST1104) (D). Indicated are the intact bacteria 
(arrow heads) and vacuoles containing degraded bacteria (asterisks).
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appendIx
Figure A1 | In vivo growth of the F. tularensis ∆capB mutants in the 
livers (A) and spleens (B) of BALB/c mice. BALB/c mice were infected 
individually with LVS (4,500 CFUs), ST1092 (5,100 CFUs), or ST1104 
(4,800 CFUs) by intranasal inoculation. Bacterial levels in the livers and spleens 
were assessed at day 7 as in Figure 3.
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